RenovaCare Inc(RCAR)
USD --+0.00%
Reward44Moderate
Risk37Moderate
📊50%Data
RCAR
+0.0 · +0.00%
USD · PINK
RenovaCare Inc | Healthcare
Capital Destroyer
Market Cap:8735
ℹ️
Reward Rating
44
Moderate
Bottom 25% (model universe)
50% data coverage
ℹ️
Risk Rating
37
Moderate
Risk Assessment
75% data coverage
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on RCAR to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is RenovaCare Inc?

, a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications.

RCAR · Verdict

Moderate reward · moderate risk

RCAR stands out on balance sheet and volatility, but watch the profitability signal.

Based on 63% data coverage

RCAR · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet78/100

    Above average

  • Volatility75/100

    Above average

Watchouts 1

  • Profitability10/100

    -569% return on equity

Model-based scoring. For information only — not financial advice.

What is RenovaCare Inc?

, a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 8.73K.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (44)

The scoring profile indicates limited reward potential at this time, with valuation and growth offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap8.73K
P/E RatioN/A
Dividend YieldN/A
52 Week High0.0001
52 Week Low0.0001
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding87M
No. of Employees1
IndustryBiotechnology
ExchangePINK
Beta-107.914
CurrencyUSD